Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 (5/1000 mg x1 tablets) at fasting state.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A(Before→ After) | Experimental |
| |
| Sequence B(After→ Before) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-1229_01 5/1000mg (Before) | Drug | single dose administration (one tablet once a day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUCt | area under the curve | pre-dose~96 hours post-dose |
| Cmax | maximum plasma concentration | pre-dose~96 hours post-dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Metro Hospital | Anyang-si | Gyeonggi-do | 14096 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007854 | Lead |
| ID | Term |
|---|---|
| D019216 | Metals, Heavy |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D008670 | Metals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DA-1229_01 5/1000mg (After) | Drug | single dose administration (one tablet once a day) |
|